Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
ConditionHypertension
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age30-80
SponsorThe Third Xiangya Hospital of Central South University
About this trial
The goal of this clinical trial is to explore the clinical efficacy and safety of individualized antihypertensive medication guided by hemodynamic phenotyping. The main questions it aims to answer are:
1. Does hemodynamics-based individualized antihypertensive therapy achieve better blood pressure control compared to guideline-based conventional therapy? 2. Does hemodynamics-based individualized therapy have comparable safety to guideline-based conventional treatment? Researchers will compare hemodynamics-based individualized antihypertensive therapy to guideline-based conventional treatment to see if the former is better than the latter.
Participants will:
1. Take hemodynamics-based individualized antihypertensive therapy or guideline-based conventional treatment every day for 8 weeks 2. Visit the clinic once every 4 weeks for checkups and tests 3. Keep a diary of their symptoms and any treatment
Eligibility criteria
Qualifiers
Aged ≥30 and <80 years, regardless of gender;
Confirmed diagnosis of hypertension meeting the criteria outlined in the 2024 Chinese Hypertension Guidelines: office blood pressure ≥140/90 mmHg and home blood pressure ≥135/85 mmHg;
Mild to moderate hypertension, with office blood pressure ranging from 140-179/90-109 mmHg;
No prior use of antihypertensive medications;
Disqualifiers
Diagnosed or highly suspected secondary hypertension;
Classified as mixed type according to hemodynamic typing;
Allergy to the intended antihypertensive medications;
Dysphagia;
Trial design
Treatments tested in this trial
- hemodynamics-based individualized antihypertensive therapy
- guideline-based conventional treatment
Treatment groups
240 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov